Pemetrexed market

Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Aug 2022
CMI2458
130 Pages
Excel & Pdf
Pharmaceutical

Summary

Pemetrexed, sold under brand name Alimta by Eli Lilly and Company is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Alimta is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases:

In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)
As a single agent for the maintenance and treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
As a single agent for the treatment of patients with recurrent metastatic nonsquamous non-small cell lung cancer (NSCLC) after prior chemotherapy
In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery

Global pemetrexed market size was valued at US$ 2,287.2 Million in 2022 and is expected to witness a CAGR of 2.2% over the forecast period (2022 – 2030).

Figure 1.Global Pemetrexed Market Share (%), by Distribution Channel, 2022

Increasing demand of hospital pharmacies due to 340b program boosts the growth of the market over the forecast period.

Increase in the demand of hospital pharmacies due to 340b program (Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients) drives the growth of the market over the forecast period. For instance, in November 2021, according to the reports published in Science direct, an online publishing database, reported that 340b hospitals provided a significantly higher average number of medication access services compared to non-340B hospitals, whereas a higher percentage of 340B hospitals reported providing the service compared to non-340B hospitals in the U.S. These services are known to improve access and quality of care for low income populations.

Pemetrexed Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 2,287.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	2.2%	2030 Value Projection:	US$ 2,728.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Strength: 100mg, 500mg By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.
Growth Drivers:	Increasing demand of hospital pharmacies due to 340b program Increasing high prevalence of non-small cell lung cancer and its high treatment rate in the U.S
Restraints & Challenges:	Side effects and complications related to parenteral route of administration

Figure 2. Pemetrexed Market Share (%), by Region, 2022

North America is expected to hold dominant position, owing to high prevalence of non-small cell lung cancer in the U.S

Increasing number of prevalence of non-small cell lung cancer in the U.S. drives the global pemetrexed market over the forecast period. For instance, American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) had been diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC, Non-small Cell Lung, (68%), stage IIIA NSCLC, Non-small Cell Lung Cancer (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).

Global Pemetrexed Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals.

Increasing termination on ongoing clinical trials during covid-19 in oncology department hindered the growth of global pemetrexed market. For instance, in July 2020, according to the reports published by The European Federation of Pharmaceutical Industries and Associations, a trade association and lobbying organization, over 20% of global oncology trials were halted because of the pandemic, with breast, prostate and lung cancer trials impacted the most.

Moreover, in March 2020, the National Institute for Health Research (NIHR) in the U.K. decided to prioritize COVID-19 related trials and paused all other new or ongoing trials, as well as non-COVID laboratory-based medical research.

Global Pemetrexed Market: Key Developments

Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period. For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, an international pharmaceutical company, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly.
For instance, on February 3, 2022, Dr. Reddy's Laboratories Ltd., a multinational pharmaceutical company along with its subsidiaries, announced that it entered into a definitive agreement to acquire Nimbus Health GmbH, a privately owned company, Dr. Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone based earn outs over the next four years. The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a treatment option for patients.

Global Pemetrexed Market: Restraints

Parenteral route of administration has to be performed under medical supervision, to avoid side effects and complications, which burdens cost on patients. The incorrect use of this therapy from parenteral route can cause liver dysfunction, refeeding syndrome, and other side effects.

Key Players

Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.

Table of Content

Table of Contents

*Browse 25 market data tables and 20 figures on “Global Pemetrexed Market” - forecast to 2030

Segmentation

Detailed Segmentation:

Global Pemetrexed Market, By Strength:
- 100mg
- 500mg
Global Pemetrexed Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Pemetrexed Market, By Region:
- North America
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Europe
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.K.
    - Germany
    - Italy
    - Spain
    - France
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Australia
    - India
    - China
    - Japan
    - ASEAN
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Strength:
    - 100mg
    - 500mg
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What are the growth estimates for the global pemetrexed market till 2030?

The global pemetrexed market is estimated to surpass US$ 2,728.1 Million by 2030.

Which are the prominent pemetrexed market players across the globe?

Major players operating in the market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.

Which segment based on distribution type, accounted for the highest demand in market of pemetrexed in 2022?

Among distribution channel, hospital pharmacies segment generated significant revenue in 2022, owing to increasing 340b program in hospital pharmacies globally.

What are the key factors driving growth of the market?

Increasing approval by the key market players in the market is one of the major factors that is expected to propel growth of market over the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the market till 2030?

The market is estimated to exhibit a CAGR of 2.2% over the forecast period.

Which region is dominating the market growth?

Among regions, North America is expected to witness significant growth over the forecast period, owing to high prevalence of non-small cell lung cancer in the U.S.